Abstract:Background & aims: Liver fibrosis and its end-stage form cirrhosis contribute to millions of deaths annually. The lack of robust antifibrotic molecules is in part attributed to the absence of any functional screens to identify molecular regulators using patient-derived primary human hepatic myofibroblasts, which are key drivers of fibrosis. Methods: Here, to identify robust regulators of fibrosis, we performed functional microRNA screenings in primary human hepatic myofibroblasts followed by in vivo validation in three independent mouse models of fibrosis (toxin, cholestasis and MASH). Results: We identified miR-190b-5p and miR-296-3p as robust antifibrotic miRNAs that suppress liver fibrosis. Notably, the expression of miR-190b-5p and miR-296-3p was found to be significantly reduced in human livers with fibrosis. Mechanistically, we discovered hyaluronan synthase 2 (HAS2) and integrin alpha-6 (ITGA6) as novel targets of miR-190b-5p and miR-296-3p, respectively. Furthermore, we demonstrated that the antifibrotic properties of miR-190b-5p and miR-296-3p are, at least in part, dependent on HAS2 and ITGA6. Finally, we showed the antifibrotic function of both miRNAs in a human liver bud model, which mimics multiple features of the human liver. Conclusions: Collectively, in our study we discovered miR-190b-5p and miR-296-3p as two novel antifibrotic miRNAs, and that HAS2 and ITGA6 contribute to miR-190b-5p- and miR-296-3p-mediated inhibition of liver fibrosis. These results provide a foundation for future research to explore the clinical utility of miR-190b-5p and miR-296-3p in fibrosis. Impact and implications: Liver fibrosis and cirrhosis contribute to millions of deaths worldwide and remain unmet medical needs. In this study, we discovered two microRNAs, miR-190b-5p and miR-296-3p, which suppress liver fibrosis in preclinical mouse models and a human liver bud model. Our promising results encourage further studies that aim to develop both miRNAs for the treatment of liver fibrosis in patients.

Downregulation of microRNA-29b in cancer and fibrosis: molecular insights and clinical implications

Mir-29 Inhibits Bleomycin-induced Pulmonary Fibrosis in Mice

TGF-β/Smad3 signaling promotes renal fibrosis by inhibiting miR-29.

MicroRNA-29b Inhibits Diabetic Nephropathy in Db/db Mice.

MicroRNA-27a-3p Inhibits Lung and Skin Fibrosis of Systemic Sclerosis by Negatively Regulating SPP1.

Upregulation of Mirna-1228-3p Alleviates TGF-β-induced Fibrosis in Renal Tubular Epithelial Cells.

MicroRNA-34a: A Novel Therapeutic Target in Fibrosis

miR-27b inhibits fibroblast activation via targeting TGFβ signaling pathway

The miR-29 family: genomics, cell biology, and relevance to renal and cardiovascular injury.

Mir‐29 Contributes to Normal Endothelial Function and Can Restore It in Cardiometabolic Disorders

MiR-542-3p controls hepatic stellate cell activation and fibrosis via targeting BMP-7.

Downregulation of Mir-30C Promotes Renal Fibrosis by Target CTGF in Diabetic Nephropathy.

MicroRNAs in Transforming Growth Factor-Beta Signaling Pathway Associated With Fibrosis Involving Different Systems of the Human Body

MicroRNA-29a Functions as a Tumor Suppressor and Increases Cisplatin Sensitivity by Targeting NRAS in Lung Cancer

Anti‐fibrotic effects and the mechanism of action of miR‐29c in silicosis

Identification and functional validation of miR-190b-5p and miR-296-3p as novel therapeutic attenuators of liver fibrosis

miR-29a-3p/THBS2 Axis Regulates PAH-Induced Cardiac Fibrosis

Effect of miR-29b on the Proliferation and Apoptosis of Pulmonary Artery Smooth Muscle Cells by Targeting Mcl-1 and CCND2

miR-29 family: A potential therapeutic target for cardiovascular disease

miR-29c is downregulated in renal interstitial fibrosis in humans and rats and restored by HIF-α activation

Diverse roles of miR-29 in cancer (review).